Aclaris Therapeutics, Inc. Initiates Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis

Published: 2025-06-02 09:06:20 ET ACRS

Published on 06/02/2025 at 09:06

Aclaris Therapeutics, Inc. announced that it has initiated a randomized, double-blind, placebo-controlled Phase 2 trial of Bosakitug (ATI-045) in patients with moderate-to-severe atopic dermatitis (AD). Common symptoms include dry, cracked, itchy patches of skin or small raised bumps, that can occur anywhere on the body. The affected skin can become inflamed, warm, thickened, and damaged with prolonged scratching.

A study by Asthma and Allergy Foundation of America noted that about 40% of those affected with the disease have moderate or severe symptoms. AD can significantly affect a patient's quality of life, with patients with moderate-to- severe AD having a higher prevalence of social dysfunction and sleep impairment.